Article
A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion.
PloS one - 1 Jan 2013
Wood Matthew P, Cole Amy L, Ruchala Piotr, Waring Alan J, Rohan Lisa C, Marx Preston, Tarwater Patrick M, Gupta Phalguni, Cole Alexander M
Abstract excerpt
Fusion inhibitors are a class of antiretroviral drugs used to prevent entry of HIV into host cells. Many of the fusion inhibitors being developed, including the drug enfuvirtide, are peptides designed to competitively inhibit the viral fusion protein gp41. With the emergence of drug resistance, there is an increased need for effective and unique alternatives within this class of antivirals. One such alternative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.